1st production QuiremSpheres

On May 21st, the first patient dosis of QuiremSpheres was processed at RTM and then shipped to the stituto Nazionale dei Tumori hospital in Milan, Italy. There it was used for the treatment of a patient suffering from hepatocellular carcinoma (HCC). QuiremSpheres® are radioactive microspheres for SIRT and are based on the isotope holmium-166.

Voor meer informatie: http://www.quirem.com/

Other news

Upcoming event

From October 15 to October 19, Radboud translational medicine will attend the 29th annual congress o...

Cooperation RTM-Alliance Medical

It is with great pleasure that we announce our cooperation with Alliance Medical Group (AMG) regardi...

Huntington’s Disease: A Review of the Known PET Imaging Biomarkers and Targeting Radiotracers

Klaudia Cybulska (postdoc radiochemistry) has written an article about Huntington's Disease. Abstra...

RTM receives marketing authorisation for Fludeoxyglucose (18F)

We are happy to announce that RTM has received marketing authorization for 18F-FDG of 17 July 2018....

News